Creon 40,000 (pancreatin) unavailable

Exocrine pancreatic insufficiency is commonly caused by chronic pancreatitis or cystic fibrosis. | SCIENCE PHOTO LIBRARY
Exocrine pancreatic insufficiency is commonly caused by chronic pancreatitis or cystic fibrosis. | SCIENCE PHOTO LIBRARY

The pancreatic enzyme replacement therapy Creon 40,000 (pancreatin) is currently unavailable, owing to manufacturing difficulties.

The manufacturer, Abbott, recommends switching patients from Creon 40,000 to Creon 25,000, which will result in a lower pill burden than switching patients to Creon 10,000.

The supply issue is due to the biologic nature of Creon 40,000 and lower-than-expected concentrations of enzymes in porcine glands needed to produce the product. It is not related to any safety issue.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases